[Combination of minimally invasive technologies in the surgery of nephrolithiasis].

Overall 62 patients coral calculi underwent percutaneous nephrolithotripsy and distant shock-wave lithotripsy (DSWL). Percutaneous nephrolithotripsy as monotherapy was effective at 47 (75.8%) patients. At 15 (24.2%) patients the residual calculi were fragmented with DSWL. Obtained positive results permit to recommend percutaneous nephrolithotripsy both as monotherapy and in combination with DSWL for the treatment of patients with coral nephrolithiasis.

[Diagnosis, prevention and treatment of renal lesion in extracorporeal shock wave lithotripsy].

The diagnosis and treatment of 120 patients with urolithiasis were made. The following examinations were made: the study of immune status and lipid peroxidation, detection of selective proteinuria, leukocyte migration inhibition reaction with autoantigens obtained from the tissues of the renopelvic segment providing additional information about renal parenchyma and immune system. The patients were divided into two groups: 70 patients of the study group received pre-, intra- and postoperative preventive pharmacotherapy, while 50 patients of the control group received standard therapy. It is shown that preventive measures in the patients of the study group aimed at raising resistance of the kidney to the shock wave and prevention of infectious-inflammatory process evidence for necessity of the above measures not only before extracorporeal shock wave lithotripsy, but also in intra- and postoperative periods.

[Advantages of the use of Andro-Gin device for treatment of secretory infertility].

The trial included 144 patients aged from 24 to 46 years with secretory infertility in the presence of chronic prostatitis of 2 to 13 year duration. The study group consisted of 96 patients who received conventional treatment in combination with physical factors provided by the unit APK-ELM-01 Andro-Gin. The control group consisted of 48 patients on conventional treatment alone. The results were processed mathematically and statistically. The patients were examined before, 2 weeks, 1 and 6 months after the treatment. Positive response was greater in the study group: better parameters of prostatic secretion, spermogram. Normalization of all the parameters occurred in 95 and 80% patients of the study and control groups, respectively. Thus, Andro-Gin is effective for treatment of chronic prostatitis with secretory infertility.

[Clinicoimmunological disorders in patients with chronic prostatitis caused by latent urogenital infection].

The study enrolled 506 males 20 to 50 years of age (mead age 30.8 +/- 0.5 years) with chronic prostatitis (CP). Group 1 consisted of 332 (65 +/- 4.1) patients with CP caused by lateral urogenital infection (LUGI) due to chlamydias, ureaplasmas, mycoplasmas, gardnerellas, herpes virus type 2. Group 2 comprised 174 patients free of LUGI. T-cell and humoral immunity parameters were assessed by T-lymphocytes CD3, T-helpers CD4, T-suppressors CD8, CD4/CD8, natural killer cells CD16 using indirect immunofluorescence. Phagocytic activity of T-lymphocytes was estimated with latex as the antigen. An etiological factor was ureaplasmas, chlamydias and others in 170 (51.2 +/- 5.4%) and 155 (46.7 +/- 5.4%) patients, respectively. Mixed infection was diagnosed in 94 (28.3 +/- 4.8%) patients. Secondary immune and interferon deficiencies were detected in 155 (30.6%) patients of both groups. The patients received etiological (antimicrobial) and pathogenetic (immunological) therapy. The highest effect was obtained in prostatitis caused by mono-LUGI. Pain and pollakiuria attenuated, the copulative function improved. The conclusion is made that CP, especially secondary to LUGI, should be treated by combination of etiotropic with immunotropic methods.

[Immune male infertility: correction with efferent therapy]. / Korrektsiia immunnogo besplodiia u muzhchin metodami éfferentnoi terapii.

Effects of plasmapheresis and hemosorption on efficacy of the treatment of autoimmune male infertility (AMI) were studied in 289 AMI males with oligoasthenozoospermia aged 19 to 37 years. The males were divided into three groups by the levels of antisperm antibodies (ASAB) in the blood and ejaculate. The study was made of cellular and humoral immunity, intensity of protein and lipid free radical oxidation and antioxidant defense. Patients of group 1 with high ASAB in the blood but low in ejaculate received a course of plasmapheresis. Patients of group 2 with high ASAB both in the blood and ejaculate were subjected to hemosorption and plasmapheresis in one contour. Group 3 patients with high ASAB in ejaculate but low in the blood received efferent therapy only after medication and photomodification of the blood. The treatment reduced elevated levels of ASAB in the blood and ejaculate, normalized free radical oxidation, cellular and humoral immunity, antioxidant defense. This resulted in improvement of spermogram parameters, efficacy of assisted reproductive technologies, higher probability of natural pregnancy in the patients' wives.

[Experience in wilaprafen treatment of chlamydial prostatitis, complicated by infertility]. / Opyt lecheniia vil'prafenom khlamidii prostitia, oslozhnennogo besplodiem.

The antichlamydial action of wilprafen was studied in patients suffering from urogenital chlamydial prostatitis complicated by infertility. An individual approach to etiotropic and pathogenetic therapy with wilprafen alone and in combination with vobenzim introduced by the authors in men with chlamydial prostatitis complicated by infertility produced a high curative effect.

[Application of the preparation "vitamax" in the complex treatment of chronic prostatitis complicated by sexual dysfunction]. / Primenenie preparata "vitamaks" v kompleksnoi terapii khronicheskogo prostatita, oslozhennogo seksual'noi disfunktsiei.

A multivitamin complex Vitamax was given to 65 patients with chronic prostatitis who retained sexual disorders after basic treatment. Mean age of the men was 41 +/- 10 years (25-67 years). The efficacy of the drug was assessed by the data obtained with Male Copulative Function questionnaire. All the patients were found to have mixed sexual dysfunction. Vitamax was taken in a dose 2 capsules a day before a morning meal, a total of 30 capsules a course. After the treatment all the patients improved their copulative function. Thus, Vitamax is an effective drug in sexual dysfunctions related to chronic prostatitis, the efficacy being higher in young men. Side effects were absent.

[Use of avelox in treating urogenital infections in men]. / Primenenie preparata aveloksa v terapii urogenital'nykh infektsii muzhchin.

We used the drug avelox, a new fluoroquinolone of the fourth generation, in therapy of urogenital infections (caused by chlamydia, mycoplasma, ureaplasma) in men. The test group consisted of 45 men with urethritis, urethroprostatitis given avelox in a single dose of 400 mg/day for 10 days. 18 control patients with urethritis took ofloxacin in a dose of 200 mg twice a day for 10 days. Examination for infection eradication was made 2 weeks and 2 months after the end of the treatment. Eradication of chlamydial infection was achieved in 18 (94.73%) patients, mycoplasma (ones in 23 (80%), ureaplasma--in 29 (86%) patients. Thus, clinical efficiency of avelox may be characterized as very good in chlamydial infection, good in ureaplasma and mycoplasma infections. Side effects occurred only in 5 patients who had short-term transient gastrointestinal disorder. Compared to ofloxacin, avelox is more effective and less toxic.

[Diagnosis and treatment of upper urinary tract infection in women as a postoperative complication for treating genital endometriosis]. / Diagnostika i lechenie infektsii verkhnikh mochevykh putei u zhenshchin kak oslozhneniia posle operatsii po povodu genital'nogo éndometrioza.

156 women operated on for genital endometriosis received treatment for infection of the upper urinary tracts diagnosed by ultrasound. The treatment was conducted only in case of normal urodynamics achieved by drainage (on demand) and comprised antibacterial therapy, efferent hemocorrection, intravascular laser irradiation of blood, hyperbaric oxigenation. A response was obtained in 98% patients.

[Wilprafen (josamycin) therapy of patients with urogenital inflammations]. / Klinicheskoe primenenie vil'prafena (dzhozamitsin) u patsientov s vospalitel'nymi zabolevaniiami urogenital'nogo trakta.

Fifty-nine male patients with urogenital infections were treated by wilprafen (josamycin). The results evidence for high efficiency of the drug in patients with urogenital inflammations and recommend it for wide use.